Sonoma Pharmaceuticals Registers Facial Spray with FDA's MoCRA
Sonoma Pharmaceuticals Registration: Sonoma Pharmaceuticals has registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022, allowing it to produce and sell these products as cosmetics in the U.S.
Expansion of Regulatory Footprint: This MoCRA registration enhances Sonoma's existing FDA-registered medical device establishment, broadening its access to the growing U.S. cosmetics and dermatology markets.
Trade with 70% Backtested Accuracy
Analyst Views on SNOA
About SNOA
About the author
5 Healthcare Stocks Soaring This Week
Top Performing Healthcare Stocks: Five healthcare stocks, including Sonoma Pharmaceuticals, Evoke Pharma, KALA Bio, Ginkgo Bioworks, and Soligenix, have shown significant week-on-week momentum gains, indicating potential breakout opportunities in the sector.
Sonoma Pharmaceuticals Highlights: Leading the pack, Sonoma Pharmaceuticals experienced a remarkable 66.73-point momentum score increase, driven by its focus on antimicrobial and dermatology products, with a 44.60% surge over the last month.
Evoke Pharma and KALA Bio Performance: Evoke Pharma's momentum score rose significantly due to its gastrointestinal treatment product, while KALA Bio saw a strong increase linked to therapies for rare ocular diseases, both showing impressive price trends.
Market Context and Momentum Ranking: The Benzinga Edge Rankings report highlights that these stocks' dramatic momentum gains reflect strong price performance and volatility, despite broader market declines in major ETFs like SPY and QQQ.
Stocks Moving Premarket: PMNT, KULR, ENLV, ORGN, And Other Gainers & Losers
Premarket Trading Activity: Notable premarket trading activity is observed, indicating potential opportunities for traders to identify breakouts or reversals before the market opens.
Stock Movements: Several stocks are showing significant percentage increases while others are experiencing notable declines in Friday's premarket session.
